Stryker (NYSE:SYK) Stock Price Target Lowered at BTIG Research

Stryker (NYSE:SYK) had its target price lowered by equities research analysts at BTIG Research from $316.00 to $304.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. BTIG Research‘s price objective points to a potential downside of 2.29% from the company’s previous close.

A number of other equities research analysts have also issued reports on SYK. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Citizens Jmp cut their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. Barclays raised Stryker to a “strong-buy” rating in a research report on Wednesday, October 7th. Evercore set a $350.00 target price on Stryker in a research note on Monday, July 6th. Finally, Argus set a $370.00 target price on Stryker in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $362.76.

Stryker Stock Performance

Shares of SYK stock opened at $311.12 on Friday. The company has a market capitalization of $119.34 billion, a price-to-earnings ratio of 32.24, a P/E/G ratio of 1.96 and a beta of 0.78. Stryker has a 1-year low of $267.00 and a 1-year high of $389.33. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock’s fifty day simple moving average is $293.56 and its 200-day simple moving average is $324.86.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. During the same quarter in the previous year, the business posted $3.19 earnings per share. The company’s revenue was up 7.6% compared to the same quarter last year. On average, sell-side analysts predict that Stryker will post 14.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 351,267 shares of company stock valued at $118,197,701 over the last quarter. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SYK. Community Bank & Trust Waco Texas boosted its stake in Stryker by 2.3% during the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after purchasing an additional 31 shares during the period. Cornerstone Financial Management LLC increased its position in Stryker by 66.0% in the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after buying an additional 31 shares during the period. NWF Advisory Services Inc. increased its position in Stryker by 2.3% in the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock worth $463,000 after buying an additional 33 shares during the period. Harold Davidson & Associates Inc. lifted its holdings in shares of Stryker by 0.4% during the first quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock worth $2,848,000 after buying an additional 34 shares during the last quarter. Finally, Private Harbour Investment Management & Counsel LLC lifted its holdings in shares of Stryker by 0.9% during the second quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company’s stock worth $1,236,000 after buying an additional 34 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter revenue increased approximately 7.6%–7.7% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19 a year earlier. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Management is navigating manufacturing constraints in the vascular business and lingering operational effects from the cybersecurity incident disclosed in March. A new CEO is also taking over as the company reassesses its growth trajectory, making the 2027 starting point a key investor focus. Stryker’s Guidance Cut Rattles Investors
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 missed the roughly $3.55–$3.56 analyst consensus, and revenue of $6.52 billion fell short of the $6.62 billion estimate. The earnings and sales misses triggered a significant selloff. Stryker Q3 2026 earnings revenue and EPS miss
• Negative Sentiment: Stryker lowered its 2026 organic net sales growth forecast to 6.5%–7.0% from 8.3%–9.3%, while adjusted EPS guidance moved to $14.80–$14.90 from $14.95–$15.10. The larger sales reduction suggests demand, supply, or execution concerns beyond a one-quarter earnings miss. Stryker Slides After Lowering 2026 Outlook
• Negative Sentiment: Analysts subsequently cut their forecasts and price targets, reinforcing concerns about slower growth, margin pressure, and the company’s ability to regain momentum in 2027. Stryker Analysts Cut Their Forecasts

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.